How to approach reversal of TNK in hemorrhagic conversion of ischemic stroke?
Considering the short half-life, at what point would it be deemed too late to administer any reversal agent, and to consider withholding it?
Answer from: at Academic Institution
There is no specific "reversal agent" for tenecteplase. Once administered, the thrombolytic effect will persist until the drug is fully metabolized and any residual plasmin has been cleared by alpha-2-antiplasmin. So, perhaps the first question is what can you do if there is an acute bleeding event ...